The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients

Dermatologic Surgery

Volumn 37, Issue 6, 2011, Pages 744-749

  LeBlanc Jr , Keith G ^a   Hughes, Matthew P ^b   Sheehan, Daniel J ^a  

^a Section of Dermatology   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACNE; ANTINEOPLASTIC ACTIVITY; APHTHOUS ULCER; CANCER GROWTH; DRUG EFFECT; DRUG MECHANISM; EDEMA; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; METASTASIS; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; SKIN CARCINOMA; SKIN SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

EID: 79959855318     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.01973.x     Document Type: Review

References (33)

1. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91. (Pubitemid 36459475)
2. Ulrich C, Schmook T, Sachse M, Sterry W, et al. Comparative epidemologiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004;30:622-7. (Pubitemid 38525892)
3. Berg D, Otley C. Skin cancer in organ transplant recipients: epidemiology, pathogenesis and management. J Am Acad Dermatol 2002;47:1-17.
4. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients-where do we stand today? Am J Transplant 2008;8:2192-8.
5. Otley C, Cherikh WS, Salsche SJ, McBride MA, et al. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol 2005;53:783-90. (Pubitemid 41501363)
6. Jensen P, Hansen S, Moller B, Leivestad T, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-86. (Pubitemid 29072794)
7. Vasudev B, Sundaram H. Cancer after renal transplantation. Curr Opin Nephrol Hypertens 2007;16:523-8. (Pubitemid 350293743)
8. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001;27:409-13. (Pubitemid 32624545)
9. Martinez JC, Otley CC, Stasko T, Euvrard S, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003;139:301-6. (Pubitemid 36330577)
10. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl 2000;6:253-62. (Pubitemid 30317219)
11. Euvard S, Kanitakis J, Decullier E, Butnaru AC, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006;81:1093-100.
12. DeGruijl FR, van Kranen HJ, Mullenders LH. UV-induced DNA damage, repair, mutations, and oncogenic pathways in skin cancer. J Photochem Photobiol B 2001;63:19-27. (Pubitemid 33040719)
13. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
14. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation
15. Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004;30:628-33. (Pubitemid 38525893)
16. Maluccio M, Sharma V, Lagman M, Vyas S, et al. Tacrolimus enhances transforming growth factor-B1 expression and promotes tumor progression. Transplantation 2003;76:597-602. (Pubitemid 37013269)
17. Jonas S, Rayes N, Neumann U, Neuhaus R, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or CsA-based quadruple immunosuppression with an interleukin-2 receptor antibody of antithymocyte globulin. Cancer 2003;80:1141-50.
18. Shumacer G, Oidtann MP, Rosewicz S, Langrehr J, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transpl Proc 2002;34:1392-3.
19. Hojo M, Morimoto T, Maluccio M, Asano T, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
20. Sehgal SN. Sirolimus: its discovery, biological properties and mechanism of action. Transplant Proc 2003;35:7S-14S.
21. Luan FL, Hojo M, Maluccio M, Yamaji K, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72. (Pubitemid 34568667)
22. Guba M, Von Breitenbuch P, Steinbauer M, Koehl G, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35. (Pubitemid 34155123)
23. Rival-Tringali AL, Euvrard S, Decullier E, Claudy A, et al. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas. Anticancer Res 2009;29:1927-32.
24. Salgo R, Gossmann J, Schofer H, Kachel HG, et al. Switch to sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10:1385-93.
25. Tessmer CS, Magalhães LV, Keitel E, Valar C, et al. Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 2006;82:1792-3. (Pubitemid 46035669)
26. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006;21:562-8. (Pubitemid 43372897)
27. Peddi VR, Jensik S, Pescovitx M, Pirsch J, et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005;19:130-6. (Pubitemid 40227864)
28. Mahe E, Morelon E, Lechaton S, Sang KH, et al. Cutaneous adverse events in renal transplant recipients reciving sirolimus-based therapy. Transplantation 2005;79:476-82. (Pubitemid 40280181)
29. Chueh SJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplant 2003;76:375-82. (Pubitemid 36928002)
30. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplant 2000;69:2085-90. (Pubitemid 30395038)
31. Troppman C, Pierce JL, Gandhi MM, Gallay BJ, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched pair pilot study. Transplant 2003;76:426-9. (Pubitemid 36928011)
32. Brewer JD, Otley CC, Christenson LJ, Phillips PK, et al. The effects of sirolimus on wound healing in dermatologic surgery. Dermatol Surg 2008;34:216-23.
33. Flechner SM. Reviewing the evidence for de novo immunosuppression with sirolimus. Transplant Proc 2008;40:S25-8.